Results 161 to 170 of about 7,354 (172)

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Lancet, The, 2019
Edward F Mckone, Damian G Downey, Eva Van Braeckel   +2 more
exaly  

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

New England Journal of Medicine, 2019
Peter Gordon Middleton, Marcus A Mall, Larry C Lands   +2 more
exaly  

Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis

American Journal of Respiratory and Critical Care Medicine, 2020
Pierre-Régis Burgel, Phillipe Reix, Isabelle Sermet-Gaudelus   +2 more
exaly  

Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis

Science Translational Medicine, 2014
Charles R Esther, Nikolay V Dokholyan, Scott H Randell   +2 more
exaly  

Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study

Lancet Respiratory Medicine,the, 2018
Margaret Rosenfeld, Claire E Wainwright, Steve Cunningham   +2 more
exaly  

Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial

Lancet Respiratory Medicine,the, 2015
Richard Moss, Patrick A Flume, Susanna A Mccolley   +2 more
exaly  

Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data

American Journal of Respiratory and Critical Care Medicine, 2015
Gregory S Sawicki, Edward F Mckone, David J Pasta   +2 more
exaly  

Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D- CFTR mutation and preserved spirometry: a randomised controlled trial

Lancet Respiratory Medicine,the, 2013
Jane Davies, Steve Cunningham, Carlos E Milla   +2 more
exaly  

Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study

Lancet Respiratory Medicine,the, 2019
Susanna A Mccolley, Caroline A Owen, Gregory S Sawicki   +2 more
exaly  

Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del

New England Journal of Medicine, 2017
Anne Munck, Edward F Mckone, Cornelis K Van Der Ent   +2 more
exaly